According to a recent study in JAMA Network Open, robotic-assisted lung surgeries take a bit longer but seem to be just as safe as video-assisted surgeries.
Robotic-assisted lung surgeries take a bit longer but seem to be just as safe as video-assisted surgeries, according to a recent study in JAMA Network Open. The study compared the operation room duration and patient outcomes for these two minimally invasive surgery techniques used for lung cancer surgery.
Lung cancer is the leading cause of cancer-related death in the United States and worldwide. If caught and diagnosed early, surgery can be used to remove lung cancer, known as lung cancer resection.
Lobectomy is the most common type of operation for lung cancer, with approximately 40,000 lobectomies performed annually in the U.S. Pulmonary lobectomy is often done using minimally invasive techniques, including robotic or video-assisted methods.
Given the growing demand for lung cancer surgeries, the cost of surgical care, as well as potential shortages of thoracic surgeons, it's crucial to compare the efficiency of these different techniques. The new study aimed to do just that.
A group of surgeons and researchers, including first author Haley I. Tupper, M.D. at the University of California Los Angeles, aimed to evaluate the differences in operative duration, length of stay, readmission and death between the two minimally invasive modalities. by focusing on the time it takes to perform robotic-assisted versus video-assisted lung lobectomies.
The retrospective cohort study included 1,088 patients aged 18 to 90 years who underwent either robotic-assisted (41%) or video-assisted (59%) lung lobectomy between January 1, 2020, and December 31, 2022 at Kaiser Permanente Northern California, a multicenter hospital system. The primary outcome measured was the duration of the operation (from cut to close) in minutes, with secondary outcomes including length of stay, readmission within 30 days, and death within 90 days.
The results showed that the robotic-assisted surgery lasted 20.6 minutes longer than video-assisted lobectomy, on average. However, there was no significant difference in the secondary patient outcomes. The lengths of stay and risk of 30-day readmission were similar between the two modalities. The 90-day death rate was too low for meaningful analysis.
While 20 minutes may not seem like much of a difference, the authors emphasize the value of this time savings in their paper. “Health care resources are finite and must be judiciously allocated,” they wrote.
“The operating room is an expensive, resource-intensive environment, and efficient use must be a priority. Inefficient use can lead to case backlogs and delay other patients’ care. From a resource utilization perspective, this study preliminarily suggests that a robot should be used selectively,” the authors concluded.
Digital Tools Utilizing Patient Health Records Improve Lung Cancer Screening Rates
July 4th 2024Researchers from the University of Utah in Salt Lake City have developed a more comprehensive, multifaceted digital tool for lung cancer screening that integrates into EHR as well as patient portals. Their paper was published in JAMA Network Open in June 2024.
Read More
Exploring the Relationship Between Immunotherapy and Body Composition in Advanced NSCLC
June 10th 2024Researchers evaluated the association between body composition from readouts generated by cross-sectional imaging and oncologic outcomes in patients with advanced or metastatic NSCLC treated with systemic immunotherapy.
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More